CHMP Delivers More Good News For Sanofi's Dupixent

 
• By Kevin Grogan

The European committee has adopted a positive opinion for Regeneron-partnered Dupixent recommending approval to include adolescents aged 12 to 17 with atopic dermatitis.

Scratching
Dupixent has significantly reduced itching and helped clear the skin of adolescents in trials • Source: Shutterstock

More from Immunological

More from Therapy Areas